Literature DB >> 11967120

Primed B cells present type-II collagen to T cells.

M Holmdahl1, M Vestberg, R Holmdahl.   

Abstract

Development of type-II collagen (CII)-induced arthritis (CIA) is dependent on a T-cell mediated activation of autoreactive B cells. However, it is still unclear if B cells can present CII to T cells. To investigate the role of B cells as antigen-presenting cells (APCs) for CII, we purified B cells from lymph nodes of immunized and nonimmunized mice. These B cells were used as APC for antigen-specific T-cell hybridomas. B cells from naïve mice did present native, triple-helical, CII (nCII) but also ovalbumin (OVA) and denatured CII (dCII) to antigen-specific T-cell hybridomas. In addition, B cells primed with nCII or OVA, but not dCII, activated the antigen-specific T-cell hybridomas two to three times better than naïve B cells. We conclude that antigen-primed B cells have the capacity to process and present CII to primed T cells, and antigen-primed antigen-specific B cells are more efficient as APC than naïve B cells. We further conclude that B cells have the potential to play an important role as APC in the development of CIA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967120     DOI: 10.1046/j.1365-3083.2002.01071.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice.

Authors:  Alexei von Delwig; Catharien M U Hilkens; Daniel M Altmann; Rikard Holmdahl; John D Isaacs; Clifford V Harding; Helen Robertson; Norman McKie; John H Robinson
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

2.  Collagen epitope expression on B cells is sufficient to confer tolerance to collagen-induced arthritis.

Authors:  Sofia E M Andersson; Tove Eneljung; Sara Tengvall; Pernilla Jirholt; Anna Stern; Louise Henningsson; Bibo Liang; Katrin Thorarinsdottir; Jan Kihlberg; Rikard Holmdahl; Inga-Lill Mårtensson; Kenth Gustafsson; Inger Gjertsson
Journal:  Arthritis Res Ther       Date:  2016-06-14       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.